500 Shades of Gray

  • Sales of its blockbuster drug (Eylea) to combat Macular Degeneration recently eclipsed $5 billion.
  • Will its early and end stage pipeline provide additional blockbuster drugs?
  • It’s stock has declined over 35% from its highs but still trounced the averages over the past 10 years.
  • Does the company represent good value at this point?  What are the risks to holding Regeneron’s shares?